BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 36093522)

  • 1.
    Tan Z; Chen M; Peng F; Yang P; Peng Z; Zhang Z; Li X; Zhu X; Zhang L; Zhao Y; Liu Y
    Transl Cancer Res; 2022 Aug; 11(8):2713-2732. PubMed ID: 36093522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LINC00638/hsa-miR-29b-3p axis-mediated high expression of CDCA4 correlates with tumor immune infiltration and hepatocellular carcinoma progression.
    Wang B; Chen L; Li Q; Zhou J; Jin W
    Transl Cancer Res; 2023 May; 12(5):1290-1306. PubMed ID: 37304553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel prognostic biomarker:
    Lai T; Peng T; Li J; Jiang Y; Liu K; Yu W; Yao N; Hu Y; Cao M; Liang J
    Transl Cancer Res; 2023 May; 12(5):1145-1164. PubMed ID: 37304536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value and immunological role of BAIAP2L2 in liver hepatocellular carcinoma: A pan-cancer analysis.
    Han X; Long W; Liu Y; Xu J
    Front Surg; 2022; 9():985034. PubMed ID: 36338652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
    Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
    PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Significance of
    Li Z; Cui Y; Duan Q; Zhang J; Shao D; Cao X; Gao Y; Wang S; Li J; Jones OD; Lei X; Wang L; Zhou X; Xu M; Ma J; Liu Y; Xu X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHMT2 is Associated with Tumor Purity, CD8+ T Immune Cells Infiltration, and a Novel Therapeutic Target in Four Different Human Cancers.
    Usman M; Hameed Y; Ahmad M; Iqbal MJ; Maryam A; Mazhar A; Naz S; Tanveer R; Saeed H; Bint-E-Fatima ; Ashraf A; Hadi A; Hameed Z; Tariq E; Aslam AS
    Curr Mol Med; 2023; 23(2):161-176. PubMed ID: 35023455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Therapeutic Targets and Prognostic Biomarkers Among Chemokine (C-C Motif) Ligands in the Liver Hepatocellular Carcinoma Microenvironment.
    Jiang Z; Xing C; Wang P; Liu X; Zhong L
    Front Cell Dev Biol; 2021; 9():748269. PubMed ID: 34938730
    [No Abstract]   [Full Text] [Related]  

  • 9. Correlation of MKI67 with prognosis, immune infiltration, and T cell exhaustion in hepatocellular carcinoma.
    Wu SY; Liao P; Yan LY; Zhao QY; Xie ZY; Dong J; Sun HT
    BMC Gastroenterol; 2021 Nov; 21(1):416. PubMed ID: 34724892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and prognostic potential of TMEM204: a pan-cancer analysis.
    Zhen Z; Li M; Zhong M; Liu J; Huang W; Ye L
    Int J Clin Exp Pathol; 2022; 15(7):258-271. PubMed ID: 35949807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of N
    Zhu HX; Lu WJ; Zhu WP; Yu S
    J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FANCI is Associated with Poor Prognosis and Immune Infiltration in Liver Hepatocellular Carcinoma.
    Hou Y; Li J; Yu A; Deng K; Chen J; Wang Z; Huang L; Ma S; Dai X
    Int J Med Sci; 2023; 20(7):918-932. PubMed ID: 37324186
    [No Abstract]   [Full Text] [Related]  

  • 13. FIGNL1 Expression and its Prognostic Significance in Pan-cancer Analysis.
    Zhen Z; Li M; Zhong M; Ye L; Ma X
    Comb Chem High Throughput Screen; 2022; 25(13):2180-2190. PubMed ID: 35232348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of let-7c on the PI3K/Akt/FoxO signaling pathway in hepatocellular carcinoma.
    Li Y; Li P; Wang N
    Oncol Lett; 2021 Feb; 21(2):96. PubMed ID: 33376529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
    Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
    Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of SLC43A2 on the tumor immune microenvironment and prognosis of liver hepatocellular carcinoma.
    Liao Y; Weng J; Chen L; Hu N; Yuan X; Wang J; He F; Cai Y; Huang Q; Wang J; Huang L
    Front Genet; 2022; 13():911378. PubMed ID: 36186480
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of lncRNA/circRNA-miRNA-mRNA ceRNA Network as Biomarkers for Hepatocellular Carcinoma.
    Chen S; Zhang Y; Ding X; Li W
    Front Genet; 2022; 13():838869. PubMed ID: 35386284
    [No Abstract]   [Full Text] [Related]  

  • 18. ACYP1 Is a Pancancer Prognostic Indicator and Affects the Immune Microenvironment in LIHC.
    Zhou L; Fu Z; Wang S; Jia J; Cheng Y; Zheng Y; Zhang N; Lu W; Yao Z
    Front Oncol; 2022; 12():875097. PubMed ID: 35586489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative Analysis of Three Novel Competing Endogenous RNA Biomarkers with a Prognostic Value in Lung Adenocarcinoma.
    Tan J; Wang W; Song B; Song Y; Meng Z
    Biomed Res Int; 2020; 2020():2837906. PubMed ID: 32802839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma.
    Zhang C; Xu H; Sui X; Wu T; Chen B; Wang S; Wang X
    J Immunol Res; 2022; 2022():7073472. PubMed ID: 35983074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.